Exelixis, Inc.

0 products tracked · names used in filings: Exelixis, Inc.

Upcoming milestones

Wed 03 Mar 2027🇺🇸 PDUFA datecompany-announcedin 109 days

zanzalintinib: PDUFA target action date (previously treated metastatic colorectal cancer (in combination with atezolizumab))

Exelixis, Inc. (EXEL); zanzalintinib; NDA; status: extended; "Zanzalintinib GI Highlights Ongoing Regulatory Review of Zanzalintinib in Combination with Atezolizumab (Tecentriq ® ) for Previously Treated Metastatic CRC with Prescription Drug User Fee Act (PDUFA) Target Action Date of March 3, 2027."; filed 2026-10-29 · source

Recent milestones

No recent milestones.

Products

No products recorded.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.